Coccidioidomycosis clinical trials
The registry lists 21 studies for Coccidioidomycosis across more than 10 countries. 4 are recruiting or about to start. 17 of them are mainly about Coccidioidomycosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Coccidioidomycosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (4) · University of Arizona (3) · Pfizer (2) · University of Minnesota (1) · F2G Ltd (1) · George R Thompson (1) · Caja Costarricense de Seguro Social (1) · University of California, San Francisco (1)
What is being tested here
Drugs under test in Coccidioidomycosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Mar 2027Olorofim in Early Coccidioidal Meningitis · Fariba Donovan
Who these studies take
Of the 2 Coccidioidomycosis studies recruiting now, 1 (50%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (50%) | 1 (50%) |
| 18 | 2 (100%) | 2 (100%) |
| 30 | 2 (100%) | 2 (100%) |
| 40 | 2 (100%) | 2 (100%) |
| 50 | 2 (100%) | 2 (100%) |
| 65 | 2 (100%) | 2 (100%) |
| 75 | 2 (100%) | 2 (100%) |
| 85 | 2 (100%) | 2 (100%) |
Across all 21 studies, recruiting or not: 19% stop at 75 or younger and 19% at 65; 33% take children; 5% are for women only and 0% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 21 of 21. search them.
- Pathogenesis and Genetics of Disseminated or Refractory CoccidioidomycosisRecruitingNCT021902661 country
- A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of CareNot yet recruitingNCT07712484Phase 2
- Platform Trial for Salvage Consolidation Therapy in Dimorphic FungiNot yet recruitingNCT07804368Phase 21 country
- Olorofim in Early Coccidioidal MeningitisRecruitingNCT07385638Phase 21 country
- Safety and PK of Nikkomycin Z for Coccidioides Pneumonia TreatmentTerminatedNCT00614666Phase 1/21 country
- To Find Effectiveness of Stretching Versus Soft Tissue Mobilization in Coccydynia in Postpartum FemalesActive, not recruitingNCT06913803Not applicable1 country
- Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal TreatmentCompletedNCT03059992Phase 38 countries
- A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.CompletedNCT065239981 country
- Safety and Pharmacokinetics of VT-1598CompletedNCT04208321Phase 11 country
- Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment OptionsCompletedNCT03583164Phase 217 countries
- An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)CompletedNCT039086321 country
- Endemic Mycoses Treatment With SUBA-itraconazole vs ItraconazoleCompletedNCT03572049Phase 2/32 countries
- Sertraline in Addition to Standard of Care Treatment for CoccidioidomycosisWithdrawnNCT02908334Phase 2
- SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to FluconazoleWithdrawnNCT04809649Phase 21 country
- Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever TreatmentTerminatedNCT03618992Not applicable1 country
- Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)TerminatedNCT02663674Phase 41 country
- POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)CompletedNCT00423267Phase 3
- Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory ArthritisCompletedNCT007968091 country
- A Multi-center Study of Spherule-Derived CoccidioidinCompletedNCT00690092Phase 31 country
- A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are CommonCompletedNCT00002325Not applicable1 country
- Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal MeningitisCompletedNCT00002010Not applicable1 country